Angewandte Chemie International Edition,
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 1, 2024
Abstract
Within
living
organisms,
numerous
nanomachines
are
constantly
involved
in
complex
polymerization
processes,
generating
a
diverse
array
of
biomacromolecules
for
maintaining
biological
activities.
Transporting
artificial
polymerizations
from
lab
settings
into
contexts
has
expanded
opportunities
understanding
and
managing
events,
creating
novel
cellular
compartments,
introducing
new
functionalities.
This
review
summarizes
the
recent
advancements
polymerizations,
including
those
responding
to
external
stimuli,
internal
environmental
factors,
that
polymerize
spontaneously.
More
importantly,
cutting‐edge
biomedical
application
scenarios
polymerization,
notably
safeguarding
cells,
modulating
improving
diagnostic
performance,
facilitating
therapeutic
efficacy
highlighted.
Finally,
this
outlines
key
challenges
technological
obstacles
remain
as
well
offers
insights
potential
directions
advancing
their
practical
applications
clinical
trials.
The
advent
of
iPSCs
has
brought
about
a
significant
transformation
in
stem
cell
research,
opening
up
promising
avenues
for
advancing
cancer
treatment.
formation
is
multifaceted
process
influenced
by
genetic,
epigenetic,
and
environmental
factors.
offer
distinctive
platform
investigating
the
origin
cancer,
paving
way
novel
approaches
to
treatment,
drug
testing,
tailored
medical
interventions.
This
review
article
will
provide
an
overview
science
behind
iPSCs,
current
limitations
challenges
iPSC-based
therapy,
ethical
social
implications,
comparative
analysis
with
other
types
also
discuss
applications
tumorigenesis,
future
tumorigenesis
highlight
successful
case
studies
utilizing
research.
conclusion
summarize
advancements
made
research
importance
continued
investment
iPSC
unlock
full
potential
these
cells.
Journal of Translational Medicine,
Год журнала:
2023,
Номер
21(1)
Опубликована: Окт. 2, 2023
Cancer
stem
cells
(CSCs)
have
emerged
as
key
contributors
to
tumor
initiation,
growth,
and
metastasis.
In
addition,
CSCs
play
a
significant
role
in
inducing
immune
evasion,
thereby
compromising
the
effectiveness
of
cancer
treatments.
The
reciprocal
communication
between
microenvironment
(TME)
is
observed,
with
TME
providing
supportive
niche
for
CSC
survival
self-renewal,
while
CSCs,
turn,
influence
polarization
persistence
TME,
promoting
an
immunosuppressive
state.
Consequently,
these
interactions
hinder
efficacy
current
therapies,
necessitating
exploration
novel
therapeutic
approaches
modulate
target
CSCs.
this
review,
we
highlight
intricate
strategies
employed
by
evade
surveillance
develop
resistance
therapies.
Furthermore,
examine
dynamic
interplay
shedding
light
on
how
interaction
impacts
progression.
Moreover,
provide
overview
advanced
that
specifically
which
hold
promise
future
clinical
translational
studies
treatment.
Nature Biotechnology,
Год журнала:
2024,
Номер
unknown
Опубликована: Май 14, 2024
Abstract
Cancer
immunotherapy
with
autologous
chimeric
antigen
receptor
(CAR)
T
cells
faces
challenges
in
manufacturing
and
patient
selection
that
could
be
avoided
by
using
‘off-the-shelf’
products,
such
as
allogeneic
CAR
natural
killer
(
Allo
CAR-NKT)
cells.
Previously,
we
reported
a
system
for
differentiating
human
hematopoietic
stem
progenitor
into
CAR-NKT
cells,
but
the
use
of
three-dimensional
culture
xenogeneic
feeders
precluded
its
clinical
application.
Here
describe
clinically
guided
method
to
differentiate
expand
IL-15-enhanced
high
yield
purity.
We
generated
targeting
seven
cancers
and,
multiple
myeloma
model,
demonstrated
their
antitumor
efficacy,
expansion
persistence.
The
also
selectively
depleted
immunosuppressive
tumor
microenviroment
antagonized
immune
evasion
via
triple
CAR,
TCR
NK
receptors.
They
exhibited
stable
hypoimmunogenic
phenotype
associated
epigenetic
signaling
regulation
did
not
induce
detectable
graft
versus
host
disease
or
cytokine
release
syndrome.
These
properties
support
potential
translation.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Янв. 3, 2024
Abstract
Cell
and
gene
therapies
hold
tremendous
promise
for
treating
a
range
of
difficult-to-treat
diseases.
However,
concerns
over
the
safety
efficacy
require
to
be
further
addressed
in
order
realize
their
full
potential.
Synthetic
receptors,
synthetic
biology
tool
that
can
precisely
control
function
therapeutic
cells
genetic
modules,
have
been
rapidly
developed
applied
as
powerful
solution.
Delicately
designed
engineered,
they
finetune
activities,
i.e.,
regulate
production
dosed,
bioactive
payloads
by
sensing
processing
user-defined
signals
or
biomarkers.
This
review
provides
an
overview
diverse
receptor
systems
being
used
reprogram
wide
applications
biomedical
research.
With
special
focus
on
four
at
forefront,
including
chimeric
antigen
receptors
(CARs)
Notch
(synNotch)
we
address
generalized
strategies
design,
construct
improve
receptors.
Meanwhile,
also
highlight
expanding
landscape
well
current
challenges
clinical
translation.
Abstract
Significant
advancements
have
been
made
in
the
application
of
chimeric
antigen
receptor
(CAR)-T
treatment
for
blood
cancers
during
previous
ten
years.
However,
its
effectiveness
treating
solid
tumors
is
still
lacking,
necessitating
exploration
alternative
immunotherapies
that
can
overcome
significant
challenges
faced
by
current
CAR-T
cells.
CAR-based
immunotherapy
against
shows
promise
with
emergence
macrophages,
which
possess
robust
phagocytic
abilities,
antigen-presenting
functions,
and
ability
to
modify
tumor
microenvironment
stimulate
adaptive
responses.
This
paper
presents
a
thorough
examination
latest
progress
CAR-M
therapy,
covering
both
basic
scientific
studies
clinical
trials.
study
examines
primary
obstacles
hindering
realization
complete
potential
as
well
strategies
be
employed
these
hurdles.
With
revolutionary
technologies
like
situ
genetic
modification,
synthetic
biology
techniques,
biomaterial-supported
gene
transfer,
provide
wider
array
resources
manipulating
tumor-associated
we
suggest
combining
advanced
methods
will
result
creation
new
era
therapy
demonstrates
improved
efficacy,
safety,
availability.
Graphical
Molecular Therapy,
Год журнала:
2024,
Номер
32(6), С. 1849 - 1874
Опубликована: Апрель 6, 2024
The
clinical
potential
of
current
FDA-approved
chimeric
antigen
receptor
(CAR)-engineered
T
(CAR-T)
cell
therapy
is
encumbered
by
its
autologous
nature,
which
presents
notable
challenges
related
to
manufacturing
complexities,
heightened
costs,
and
limitations
in
patient
selection.
Therefore,
there
a
growing
demand
for
off-the-shelf
universal
therapies.
In
this
study,
we
have
generated
CAR-engineered
NKT
(
Trends in Pharmacological Sciences,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Chimeric
antigen
receptor
(CAR)-T
cell
therapy
has
transformed
the
treatment
landscape
for
hematological
cancers.
However,
achieving
comparable
success
in
solid
tumors
remains
challenging.
Factors
contributing
to
these
limitations
include
scarcity
of
tumor-specific
antigens
(TSAs),
insufficient
CAR-T
infiltration,
and
immunosuppressive
tumor
microenvironment
(TME).
Vaccine-based
strategies
are
emerging
as
potential
approaches
address
challenges,
enhancing
expansion,
persistence,
antitumor
efficacy.
In
this
review,
we
explore
diverse
vaccine
modalities,
including
mRNA,
peptide,
viral
vector,
dendritic
(DC)-based
vaccines,
their
roles
augmenting
responses.
Special
focus
is
given
recent
clinical
advancements
combining
mRNA-based
vaccines
with
genitourinary
addition,
discuss
crucial
considerations
optimizing
dosing,
scheduling,
delivery
maximize
synergy,
aiming
refine
combination
strategy
improve
efficacy
safety.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Сен. 6, 2023
The
treatment
of
cancer
was
revolutionized
within
the
last
two
decades
by
utilizing
mechanism
immune
system
against
malignant
tissue
in
so-called
immunotherapy.
Two
main
developments
boosted
immunotherapy:
1)
use
checkpoint
inhibitors,
which
are
characterized
a
relatively
high
response
rate
mainly
solid
tumors;
however,
at
cost
serious
side
effects,
and
2)
chimeric
antigen
receptor
(CAR)-T
cells,
were
shown
to
be
very
efficient
hematologic
malignancies,
but
failed
show
clinical
effectiveness
tumors
until
now.
In
addition,
active
immunization
individual
is
emerging,
first
products
have
reached
approval.
These
new
options
cost-intensive
not
financially
compensated
health
insurance
many
countries.
Hence,
strategies
must
developed
make
immunotherapy
affordable
improve
cost-benefit
ratio.
this
review,
we
discuss
following
strategies:
leverage
antigenicity
“cold
tumors”
with
reagents,
microbiome-based
as
markers
or
therapeutics,
3)
apply
measures
that
adoptive
cell
therapy
(ACT)
cheaper,
e.g.,
off-the-shelf
products,
4)
immunotherapies
offer
cheaper
platforms,
such
RNA-
peptide-based
vaccines
shared
common
antigens
instead
highly
personal
antigens,
5)
small
set
predictive
biomarkers
“sequence
everything”
approach,
6)
explore
immunohistochemistry
may
direct
therapies.
